ClinicalTrials.Veeva
Menu

Find clinical trials for Prostate Cancer in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Prostatic Cancer
Breast Cancer
Cancer
Ovarian Cancer
Neoplasm Metastasis
Non-Small-Cell Lung Carcinoma
Colorectal Cancer

Prostate Cancer trials near Milano, Lombardia, ITA:

Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (RAPSON)

prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC)Open-label, randomized phase II trial in ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: Radium-223
Drug: Docetaxel

Phase 2

Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Milano, Italy and 15 other locations

(PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer...

Not yet enrolling
Metastatic Prostate Cancer
Drug: AZD2287 (Imaging agent)
Drug: Docetaxel

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milan, Italy and 32 other locations

The aim of this study is to assess the safety and dosimetry of imaging with \[68Ga\]Ga-OncoACP3 in patients with prostate cancer....

Enrolling
Prostate Cancer
Drug: [68Ga]Ga-OncoACP3

Phase 1

Philogen
Philogen

Bergamo, Bergamo, Italy and 1 other location

The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer...

Enrolling
Metastatic Prostate Cancer
Drug: AZD9574
Drug: AZD0516

Phase 1, Phase 2

AstraZeneca
AstraZeneca

Milan, Italy and 51 other locations

and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytotoxic chemo ...

Active, not recruiting
Metastatic Castration-resistant Prostate Cancer
Drug: abiraterone acetate
Drug: olaparib

Phase 3

AstraZeneca
AstraZeneca

Milan, Italy and 131 other locations

with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm)....

Enrolling
Prostate Cancer
Drug: Saruparib
Drug: Abiraterone + Prednisolone/Prednisone

Phase 3

AstraZeneca
AstraZeneca

Milan, Italy and 329 other locations

Locations recently updated

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's...

Enrolling
Metastatic Castration-resistant Prostate Cancer
Drug: Xaluritamig
Drug: Docetaxel

Phase 3

Amgen
Amgen

Milan, Italy and 135 other locations

This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide a...

Enrolling
Metastatic Hormone-sensitive Prostate Cancer
Drug: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Drug: Docetaxel

Phase 3

Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD

Milan, Italy and 55 other locations

Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I\&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate...

Active, not recruiting
Metastasis From Malignant Tumor of Prostate
Drug: 177Lu-PSMA-I&T
Drug: Abiraterone with Prednisone or Enzalutamide

Phase 3

Curium

Milan, Italy and 51 other locations

efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone-Sensitive Prostate...

Enrolling
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Drug: Abiraterone
Drug: Tulmimetostat

Phase 1, Phase 2

Novartis
Novartis

Rozzano, MI, Italy and 30 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems